Nuvelo is committed to building a valuable business through the discovery, development and commercialization of life improving therapeutics for human disease.

9/24/2003

Click here to start

Table of Contents

Nuvelo is committed to building a valuable business through the discovery, development and commercialization of life improving therapeutics for human disease.

Advancing Compounds Through the Clinic:Alfimeprase

Nuvelo & Amgen 50/50 Partnership

Alfimeprase Development is Moving Rapidly

Phase I TrialAngiograms: Pre and post Alfimeprase dosing

Important Lead Indication: Acute Peripheral Arterial Occlusion

Second Indication: Catheter Occlusion

>$500MM U.S. Market

Value Driving Drug Discovery Engine

Maximizing Potential Through Strategic Business Development Activity

Selected Key Financials

Near-Term Milestones

Additional Slides

Systemic Inactivation of Alfimeprase Allows for Potentially Fewer Side-Effects

Alfimeprase Patent Protection is Solid

Alfimeprase Lyses Clots More Rapidly than Other Thrombolytics

Author: ---